ICD-10 E76.02 is officially defined as "Hurler-Scheie syndrome." code E76.02 is referenced in 3 tracked payer policy changes from Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E76.02 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
This is a routine annual reissue of the Enzyme Replacement Therapy for Mucopolysaccharidosis policy with no substantive changes to coverage criteria, dosing, or billing codes. The policy maintains coverage for five ERT medications (Aldurazyme, Elaprase, Vimizim, Naglazyme, Mepsevii) with existing medical necessity requirements and FDA-approved dosing schedules.
This is a routine annual reissue of Independence Blue Cross Medicare Advantage policy MA08.034d with NO substantive changes to coverage criteria, medical necessity requirements, dosing, or billing codes for enzyme replacement therapy for mucopolysaccharidosis (MPS). The policy remains effective 01/01/2024 and applies to New Jersey Medicare Advantage members only. No billing workflow changes are required.
This is a routine annual reissue of Independence Blue Cross policy 08.00.70e on Enzyme Replacement Therapy for Mucopolysaccharidosis with no substantive changes to coverage criteria, dosing, or billing codes. The policy maintains coverage for five FDA-approved enzyme replacement therapies (Aldurazyme, Elaprase, Vimizim, Naglazyme, and Mepsevii) when medical necessity criteria are met.
Watch E76.02
Get one email when a payer policy names E76.02, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.